<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140005107A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140005107</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13980749</doc-number><date>20120119</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>775</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>775</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc></classifications-cpc><classification-national><country>US</country><main-classification>514  69</main-classification></classification-national><invention-title id="d0e43">APOLIPOPROTEIN AIV AS AN ANTIDIABETIC PEPTIDE</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>61434196</doc-number><date>20110119</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only"><addressbook><last-name>Tso</last-name><first-name>Patrick</first-name><address><city>Cincinnati</city><state>OH</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="01" app-type="applicant" designation="us-only"><addressbook><last-name>Davidson</last-name><first-name>Sean</first-name><address><city>Cincinnati</city><state>OH</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="02" app-type="applicant" designation="us-only"><addressbook><last-name>Woods</last-name><first-name>Stephen</first-name><address><city>Cincinnati</city><state>OH</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="03" app-type="applicant" designation="us-only"><addressbook><last-name>Wang</last-name><first-name>Fei</first-name><address><city>Cincinnati</city><state>OH</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Tso</last-name><first-name>Patrick</first-name><address><city>Cincinnati</city><state>OH</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Davidson</last-name><first-name>Sean</first-name><address><city>Cincinnati</city><state>OH</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Woods</last-name><first-name>Stephen</first-name><address><city>Cincinnati</city><state>OH</state><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>Wang</last-name><first-name>Fei</first-name><address><city>Cincinnati</city><state>OH</state><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>UNIVERSITY OF CINCINNATI</orgname><role>02</role><address><city>Cincinnati</city><state>OH</state><country>US</country></address></addressbook></assignee></assignees><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/US12/21802</doc-number><kind>00</kind><date>20120119</date></document-id><us-371c124-date><date>20130917</date></us-371c124-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Methods for treating type two diabetes mellitus in a subject in need thereof and pharmaceutical compositions for the treatment of type two diabetes mellitus are disclosed. The methods include administering an effective amount of apolipoprotein A-IV to the subject. The pharmaceutical composition includes apolipoprotein A-IV formulated for administration to a subject for the treatment of type two diabetes mellitus. Also disclosed are methods for substantially restoring glucose tolerance in a subject in need thereof to a normal level and methods for lowering blood glucose levels in a subject in need thereof.</p></abstract></us-patent-application>